2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.40 (Poster) Treatment Patterns and Survival Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Survival at a Safety-Net Hospital

PP01.40 (Poster) Treatment Patterns and Survival Outcomes of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Survival at a Safety-Net Hospital

Back to course

Pdf Summary

A recent study conducted at John Peter Smith Hospital in Fort Worth, Texas explored the treatment patterns and survival outcomes of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients. The study aimed to determine if underserved cancer patients at a safety-net hospital benefit from ICI treatments. <br /><br />The study analyzed the data of 195 patients diagnosed with stages IIIB/IIIC/IV NSCLC at the hospital from January 2017 to December 2021. Patients with driver mutations were excluded from the analysis. The electronic records were reviewed for programmed death ligand 1 (PDL-1) testing and first-line treatments. Overall survival was calculated from the date of diagnosis to death or the last chart entry before May 31, 2023.<br /><br />The results showed that patients who received first-line chemoimmunotherapy or immunotherapy had better survival compared to chemotherapy alone, regardless of PDL-1 results. Patients who did not undergo PDL-1 testing likely had poor performance status and were not eligible for treatment. Stage III patients with PDL-1 expression of 50% who were not candidates for chemoradiation could benefit from immunotherapy instead of palliative radiation.<br /><br />The study also found that patients who had PDL-1 testing performed, regardless of the results, had favorable survival compared to those who were not tested. Among the 195 lung cancer patients, 67 did not undergo PDL-1 testing and had a median overall survival of 3.0 months.<br /><br />Overall, the study suggests that ICI treatments, such as chemoimmunotherapy and immunotherapy, can improve survival outcomes in advanced NSCLC patients. The researchers emphasize the importance of extending the benefit of ICIs to as many patients as possible and ensuring equitable access to these treatments for underserved populations.<br /><br />The study was conducted as part of the University of North Texas Health Science Center's Pediatric Research Program in collaboration with John Peter Smith Hospital.

Asset Subtitle

Krishti Sabloak

Keywords

John Peter Smith Hospital

Fort Worth

Texas

immune checkpoint inhibitors

non-small cell lung cancer

treatment patterns

survival outcomes

underserved cancer patients

PDL-1 testing

chemoimmunotherapy